Roth's $212 price target implies an additional upside of 32% for shares of Insmed, which have already rallied 160% in the last 12 months.
Get this delivered to your inbox, and more info about our products and services.
The investment bank upgraded the pharma stock to overweight from equal weight.
BofA analysts are bullish on this German medtech name ahead of its full-year earnings report.
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
The investment bank upgraded the pharmaceutical name to buy from neutral.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
The bank initiated the clinical-stage biotechnology firm at a buy rating.
